{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:00:12Z","timestamp":1760144412116,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.rmr.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T03:26:05Z","timestamp":1657855565000},"page":"626-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pneumopathie immuno-induite\u00a0: un diagnostic diff\u00e9rentiel de la pneumopathie \u00e0 SARS-CoV-2"],"prefix":"10.1016","volume":"39","author":[{"given":"B.","family":"Nigen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-L.","family":"Ch\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Liberge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.-X.","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.rmr.2022.07.001_bib0175","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.07.001_bib0180","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3\u00a0randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2022.07.001_bib0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1\u00a0blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.07.001_bib0190","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.07.001_bib0195","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.rmr.2022.07.001_bib0200","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1\u00a0\u2013\u00a0related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.07.001_bib0205","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1\u00a0therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rmr.2022.07.001_bib0210","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2022.07.001_bib0215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.rmr.2022.07.001_bib0220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.rmr.2022.07.001_bib0225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","article-title":"Severe toxicity from checkpoint protein inhibitors: what intensive care physicians need to know?","volume":"9","author":"Lemiale","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.rmr.2022.07.001_bib0230","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2022.07.001_bib0235","doi-asserted-by":"crossref","first-page":"E305","DOI":"10.3390\/cancers11030305","article-title":"Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features","volume":"11","author":"Porcu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.rmr.2022.07.001_bib0240","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0245","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1\u00a0therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0250","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1753465816636557","article-title":"Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"10","author":"Abdel-Rahman","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.rmr.2022.07.001_bib0255","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0260","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2020.12.016","article-title":"Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis","volume":"145","author":"Duchemann","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rmr.2022.07.001_bib0265","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0270","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4\u00a0and PD-1\/PD-L1\u00a0inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.rmr.2022.07.001_bib0275","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1\u00a0inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0280","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0285","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0290","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.rmr.2022.07.001_bib0295","doi-asserted-by":"crossref","first-page":"190058","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2022.07.001_bib0300","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1\u00a0inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2022.07.001_bib0305","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40134-017-0256-2","article-title":"Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy","volume":"5","author":"Widmann","year":"2016","journal-title":"Curr Radiol Rep"},{"key":"10.1016\/j.rmr.2022.07.001_bib0310","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-3-030-41008-7_13","article-title":"Immune-related adverse events: pneumonitis","volume":"1244","author":"Zhong","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.rmr.2022.07.001_bib0315","first-page":"249","article-title":"Imagerie de la pneumonie COVID-19","volume":"3","author":"Lod\u00e9","year":"2020","journal-title":"J Imagerie Diagn Interv"},{"key":"10.1016\/j.rmr.2022.07.001_bib0320","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0325","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.rmr.2022.07.001_bib0330","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2022.07.001_bib0335","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225937","article-title":"Severe pneumonitis refractory to steroids following anti-PD-1\u00a0immunotherapy","author":"Andruska","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.rmr.2022.07.001_bib0170","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842522002583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842522002583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:22:45Z","timestamp":1760106165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842522002583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0761842522002583"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2022.07.001","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumopathie immuno-induite\u00a0: un diagnostic diff\u00e9rentiel de la pneumopathie \u00e0 SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}